Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “MASTECTOMY”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 505 records · Page 28Linked to original sources
PubMed2000

Envelope mastectomy with immediate reconstruction (EMIR).

AIMS: To develop an oncologically safe and aesthetically acceptable technique for mastectomy, using a muscle flap and tissue expander through one incision. METHODS: Twelve consecutive patients (mean age 40) underwent an envelope mastectomy (skin and nipple sparing), with immediate reconstruction with a latissimus dorsi muscle flap and tissue expander. Assessment of cosmesis was by review of pre- and post-operative photographs by an independent observer. RESULTS: During follow-up there have been no recurrences. Assessment of cosmesis gave a score of 44 out of 48 (92%). One prosthesis was removed due to erosion of the prosthesis through the skin. CONCLUSIONS: In patients with large lesions, multi-focal lesions (both invasive and in situ) and recurrent phyllodes tumours may undergo an oncologically safe mastectomy with immediate reconstruction through a single incision that is inconspicuous being in the mid-axillary line. Although follow up is only 8.5 months, long-term studies are being undertaken.

Adult↗
PubMed2000

Circum-areolar mastectomy with immediate reconstruction (CAMIR).

AIMS: To develop an oncologically safe and aesthetically acceptable technique for mastectomy using a myocutaneous flap and tissue expander for patients with neoplastic involvement of the nipple. METHODS: Fourteen consecutive patients (mean age 40 years) underwent a circum-areolar mastectomy with immediate reconstruction using a latissimus dorsi myocutaneous flap and tissue expander. Assessment of cosmesis was by review of pre- and post-operative photographs by an independent observer. RESULTS: During a mean follow-up of 11.4 months there have been no local recurrences. There were two deaths: pulmonary embolus (one) and distant metastatic disease (one). Assessment of cosmesis gave a score of 47 out of 56 (84%). CONCLUSIONS: In patients with tumours involving the nipple, mastectomy with immediate reconstruction may be used to achieve a good cosmetic result. The replacement nipple is fashioned from a circle of skin attached to the latissimus dorsi myocutaneous harvest.

Adult↗
PubMed2001

A comparison of 5-day and 8-day drainage following mastectomy and axillary clearance.

AIMS: Mastectomy and axillary clearance are standard operations for the treatment of breast carcinoma. Drainage of the mastectomy site and axilla is often required to allow accumulating blood and inflammatory fluids to escape. However, there is a lack of data relating to how long suction drains should stay in situ after major breast surgery. In our study we have tried to address this deficit by comparing the efficacy of 5-day post-operative drainage with 8-day post-operative drainage. METHODS: Patients requiring mastectomy and axillary clearance were randomized to having drains removed on day 5 or day 8 post-operatively. The number of lymphoceles, aspirations and total aspiration volumes in chest and axillary drains were compared. RESULTS: From a total of 121 patients enrolled into the study, 64 patients were randomized to the 5-day group and 57 to the 8-day group. There were significant differences regarding the number of aspirations and total aspiration volumes in chest and axillary drains between the two groups, favouring 8-day drainage. However the number of lymphoceles drained in the 5-day group was significantly higher than the 8-day group. CONCLUSIONS: Five-day post-operative drainage is as safe as 8-day post-operative drainage in the management of patients undergoing major breast surgery, but results in an increase in lymphocele aspiration and aspiration volume.

Axilla↗
PubMed2001

Breast conservation, mastectomy and axillary surgery in New South Wales women in 1992 and 1995.

To measure the increase in uptake of BCT in NSW and its determinants, we examined Cancer Registry records of 2020 women with breast cancer in 1992 and 2883 in 1995 linked to records of their surgical treatment in the NSW Inpatient Statistics' Collection. In parallel, we examined trends and determinants in axillary surgery for breast cancer. Breast conservation increased from 39% of breast cancer in 1992 to 45% in 1995, mainly in women with the smallest cancers. In 1995, mastectomy was still most common in women with larger cancers (OR for breast cancers 3+ cm relative to <1 cm = 5.6, 95% CI 2.9-10.7) and cancers that had spread beyond the breast (OR = 2.0, 95% CI 1.4-2.7 relative to localized to the breast). Urban women had fewer mastectomies than rural women. Axillary surgery, common in 1992 (78%) and 1995 (82%), fell steeply with increasing age and more often accompanied mastectomy (93% in 1995) than BCT (67% in 1995). In 1995 the odds for axillary surgery were some two-fold or more higher for all cancers 1 cm or more in diameter compared with those <1.0 cm and highest for 2.0-2.9 cm cancers (OR = 3.3 95% CI 1.7-6.7 relative to <1.0 cm). Regional spread of the cancer at diagnosis was not a strong predictor. In the absence of collection of treatment data by cancer registries, linkage of cancer registry records with hospital inpatient data is an effective alternative for monitoring breast cancer treatment trends.

Adult↗
PubMed1980

[Treatment of malignant and premalignant diseases of the breast by subcutaneous mastectomy with simultaneous augmentation mammoplasty (author's transl)].

Among 6 patients with small intra-ductal carcinomas of the breast two had local recurrences of cancer following unilateral subcutaneous mastectomy. We therefore limit subcutaneous mastectomy to pre-cancerous conditions and then use a bilateral subcutaneous mastectomy with augmentation mammoplasty. Our methods and results in 28 cases are described. We think that the removal of approximately 95% of the breast tissue is enough assurance to the patient that no cancer will develop later. The patients are happy with the cosmetic results and abandon their cancerophobia generated by long term diagnostic observation.

Adult↗
PubMed1981

Comparing radical mastectomy with quadrantectomy, axillary dissection, and radiotherapy in patients with small cancers of the breast.

From 1973 to 1980, we carried out a controlled study at the National Cancer Institute in Milan to consider the value of a conservative procedure in patients with breast cancer of small size. We randomized 701 patients with breast cancer measuring less than 2 cm in diameter and with no palpable axillary lymph nodes to Halsted radical mastectomy or to "quadrantectomy" with axillary dissection and radiotherapy to the ipsilateral residual breast tissue. We treated 349 patients with Halsted mastectomy and 352 with quadrantectomy. The two groups were comparable in age distribution, size and site of primary tumor, menopausal status, and frequency of axillary metastases. There were three local recurrences in the Halsted group and one in the quadrantectomy group. Actuarial curves showed no difference between the two groups in disease-free or overall survival. From these results, mastectomy appears to involve unnecessary mutilation in patients with breast cancer of less than 2 cm and no palpable axillary nodes.

Aged↗
PubMed1975

Sex therapy and mastectomy.

Because the emotional trauma associated with a mastectomy exceeds the physical trauma, the recovery of the woman is greatly affected by the response of her husband or lover. Sex therapy, therefore, involves the couple. The approach described here is aimed at assisting the couple to confront and intergrate the mastectomy experience. The use of a prosthesis is discouraged during intercourse because it delays such confrontation; certain sex therapy exercises (body imagery and sensate focus) are usually recommended because they facilitate confrontation and acceptance. These, modified for the circumstances, are described. It is suggested that intercourse be attempted as early as possible, and that if physical weakness or psychological trepidation intervenes, the physical desire and caring of the husband be expressed nonetheless. The "professional" attitudes that psychotherapy is always indicated for mastectomy patients and that the proper role of the husband is matter-of-fact denial are rejected; emphasis is placed on the beneficial consequences of sharing of all emotions.

Body Image↗
PubMed1982

Sexual functioning after mastectomy: life vs. lab.

In research on the effect of mastectomy on sexual functioning, 13 Caucasian and Oriental women, aged 34 to 57, with breast cancer and subsequent mastectomy were compared with 11 similarly aged married women to ascertain physiological and emotional reactions to erotic audio and video materials; attitudes about self, body image and attractiveness; and perceptions of sexuality and relationships with men. Similarity existed between groups on most measures with controls only showing significant positive correlation between physiological and subjective indices of sexual arousal. Anxiety in mastectomies likely interfered with attention to bodily cues and cognitive labeling of those as sexual arousal.

Adaptation, Psychological↗
PubMed1997

Ultrasound-guided fine needle aspiration biopsy in the diagnosis of breast cancer recurrence after mastectomy.

PURPOSE: To define the accuracy and clinical impact of fine needle aspiration biopsy (FNAB) in diagnosing recurrent breast cancer after mastectomy. MATERIAL AND METHODS: The results of ultrasonography (US) and US-guided FNAB of 175 lesions located at the mastectomy site or in the ipsilateral axilla were reviewed. The final diagnosis was recurrent cancer in 77 cases and benign lesion in 98 cases, as verified by histological examination (n = 77) or follow-up (n = 98). RESULTS: FNAB yielded a representative aspirate in 92.6% of cases. The sensitivity, specificity and overall accuracy of FNAB cytology were 96.1%, 89.8% and 92.6% respectively. US and FNAB cytology were complementary methods in recurrent cancer diagnosis. The cytologic examination increased the specificity of US. The only recurrent tumor which appeared benign both sonographically and cytologically was removed because of a suspicious finding at palpation. FNAB cytologic diagnosis was found to have a clinical impact in 92.2% of the recurrent cases. CONCLUSION: US-guided FNAB provided an accurate adjunct to clinical examination and mammography for diagnosing and excluding breast cancer recurrence after mastectomy.

Adult↗
PubMed1975

Segmental mastectomy plus radiation therapy for stage I cancer of the breast.

Segmental mastectomy (surgical removal of the palpable tumor mass with a shell of normal tissue) plus irradiation to the entire remaining breast and regional lymph nodes is commonly used in other countries as a treatment for Stage I cancer of the breast. It is not, however, generally practiced or accepted in the United States. Adequate postoperative irradiation consisting of 4,500-5,000 rads to regional lymph nodes and a slightly higher dose to the breast itself will eliminate more than 90% of remaining subclinical tumor, as evidence by very low local recurrence rates. Many patients having local recurrence may then be salvaged by mastectomy or axillary node dissection. Equal five- and ten-year survival rates are obtained compared with radical mastectomy with less physical and psychological morbidity for the patient. While this treatment is not suitable for all Stage I cases, its efficacy should be more widely recognized.

Breast Neoplasms↗
PubMed2002

p53 and c-erbB-2 but not bcl-2 are predictive of metastasis-free survival in breast cancer patients receiving post-mastectomy adjuvant radiotherapy in Taiwan.

BACKGROUND: Patients with breast cancer often receive radiotherapy after mastectomy if they are at a high risk of local recurrence, but the prognosis varies among patients. We conducted a study to evaluate p53, bcl-2 and c-erbB-2 as predictors of prognosis in breast cancer patients receiving post-mastectomy radiotherapy, which has not been well defined in the Taiwanese population. METHODS: We recruited 74 consecutive patients with primary operable breast cancer who were treated with mastectomy followed by locoregional radiotherapy and studied the presence of p53, bcl-2 and c-erbB-2 expressions in tumor tissues by immunohistochemical staining. Associations between the protein expressions and clinical outcomes, including local recurrence-free survival (LRFS), metastasis-free survival (MFS) and overall survival (OS), were evaluated. RESULTS: The median follow-up time was 55 months. Expressions of p53, bcl-2 and c-erbB-2 were observed in 14 (19%), 28 (38%) and 39 (53%) patients, respectively. Both p53 and c-erbB-2 were significant predictors of MFS. The 5-year MFS for p53-negative and p53-positive tumors were 61.2 and 35.7% (P = 0.01) and 5-year MFS for c-erbB-2-negative and c-erbB-2-positive tumors were 71.3 and 42.4% (P = 0.01). Whereas expression of bcl-2 protein is associated with favorable clinicopathological features, it was not related to LRFS, MFS or OS. Multivariate analyses confirmed c-erbB-2 and p53 expressions as predictors of MFS independent of tumor size, histological grading and lymph node involvement. CONCLUSION: Expressions of p53 and c-erbB-2 are independent predictors of MFS in this Taiwanese population. Further research should be conducted on their application in the treatment and follow-up of patients.

Adult↗
PubMed2003

Patterns of care study in Japan: analysis of patients subjected to mastectomy followed by radiotherapy.

BACKGROUND: Two prospective studies reported in 1997 demonstrated that postoperative radiotherapy after mastectomy was not only associated with a higher loco-regional control rate but also with a higher overall survival rate. The purpose of this study is to clarify the processes of care for patients undergoing mastectomy and postoperative radiotherapy in Japan. METHODS: A national survey carried out in 1998-2000, involving 79 Japanese institutions by two-stage cluster sampling of institutions and patients, disclosed that 1124 patients with breast cancer had been treated between 1995 and 1997. Mastectomy followed by radiotherapy was performed on 258 patients. RESULTS: The compliance rates for pre-treatment evaluation, including history, physical examination and mammography, averaged approximately 50% (24-81%). The chest wall was irradiated in only 19% of the patients and regional node irradiation was carried out for 70-86%. Radiation treatment planning with the aid of computed tomography was done in only 29% of patients (university hospitals or cancer centers, 39%; other hospitals, 17%; P = 0.001). Hormonal therapy was administered to 56% of the patients who showed no endocrine responsiveness. Non-intensive chemotherapy, which did not include the use of anthracycline or taxol, was used in 55% of the patients who received chemotherapy. CONCLUSIONS: There is room for improvement regarding some aspects of radiotherapy and adjuvant systemic therapies. Especially in the field of radiotherapy, significant differences were found among the treatment techniques employed in various institutions.

Adult↗
PubMed1990

Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more.

In 165 women with breast cancer who were candidates for mastectomy because the largest diameter of the tumor was 3 cm or more, we administered primary chemotherapy in the attempt to substitute conservative for mutilating surgery. We then systematically quantitated tumor reduction by clinical, radiologic, and histopathologic evaluations. Five consecutive groups of 33 patients received cyclophosphamide, methotrexate, and fluorouracil (CMF); fluorouracil, doxorubicin (Adriamycin), and cyclophosphamide (FAC); or fluorouracil, epirubicin, and cyclophosphamide (FEC). The regimens for the five groups were as follows: group 1, three cycles of CMF; group 2, four cycles of CMF; group 3, three cycles of FAC; group 4, four cycles of FAC; and group 5, three cycles of FEC. In response to primary chemotherapy, 157 of the 161 assessable patients showed measurable tumor shrinkage; progressive disease was documented in four. Tumor shrinkage to less than 3 cm was documented in 127 (81%) of the 157 women subjected to surgery, thus allowing a breast-saving procedure, rather than modified radical mastectomy, in these 127 women. Histopathologic complete remission was documented in seven patients. Tumor response was unrelated to age, menopausal status, DNA content (ploidy), [3H]thymidine-labeling index, drug combination used, or number of treatment cycles in excess of three. The degree of response was inversely proportional to the initial tumor size, and the frequency of response was greater in receptor-negative tumors. Severe vomiting and hair loss were less frequent with CMF than with anthracycline-containing regimens, and the frequency of severe leukopenia and thrombocytopenia was minimal. Our results challenge the classical indication for primary mastectomy by showing that use of full-dose primary chemotherapy, sequentially combined with conservative surgery and radiation, can offer an effective and safe alternative to women concerned about the preservation of body integrity.

Antineoplastic Combined Chemotherapy Protocols↗
PubMed1994

Local recurrences following mastectomy: support for the concept of tumor dormancy.

BACKGROUND: Local or regional recurrence of breast cancer occurs in 5%-30% of patients treated by Halsted radical or modified radical mastectomy. Lag time between treatment and recurrence varies widely, and it is not known whether the recurring tumor grows at a constant growth rate or at a more rapid rate after a period of tumor dormancy. PURPOSE: This study was undertaken to discriminate between the above-mentioned hypotheses, i.e., determine whether a tumor that recurs after mastectomy grows at a constant rate or whether it grows rapidly following a period of tumor dormancy. METHODS: A series of 122 patients with local recurrence as a first event after mastectomy for resectable breast cancer was evaluated. We measured the diameter of the recurring tumor (Dr) in each patient and calculated the diameter that the recurring tumor could have reached at the immediately preceding physical examination (Dpe), when no local relapse had yet been detected, by assuming an exponential growth during the treatment-free interval. For patients who had a calculated diameter Dpe that was large enough to have been detected at the previous examination, we assumed that a tumor 5 mm in diameter had been mistakenly missed, and the expected corresponding tumor diameter at the time of detection (Drc) was calculated. Finally, the minimum growth rate (mGR) consistent with the sequence "no detection-->recurrence of diameter Dr" was obtained by assuming an exponential growth from the tumor volume corresponding to a diameter 1 mm less than the diameter detection threshold. RESULTS: A wide overlap between Dr and Dpe values was observed. Seventy-two (59%) of 122 Dpe values were larger than the minimum Dr; 18 (15%) were even larger than the median Dr value. The difference between expected and observed detection rates was highly significant (P < .0001). Furthermore, when treatment-free intervals were longer than 4 years, the difference between median Dr and median Dpe values failed to reach statistical significance. The Drc values were significantly lower than the related Dr values, while the mGR values were significantly higher than the corresponding growth rates (paired sample t test: P < .001). CONCLUSION: This study provides evidence that the hypothesis of uninterrupted constant growth of locally recurring breast tumors should be rejected, as it implies a statistically significant departure from observed data. Our results suggest that a period of tumor dormancy followed by more rapid growth could provide an alternative and more reasonable description of tumor recurrence.

Adult↗
PubMed2001

Risk-reduction mastectomy: clinical issues and research needs.

Risk-reduction mastectomy (RRM), also known as bilateral prophylactic mastectomy, is a controversial clinical option for women who are at increased risk of breast cancer. High-risk women, including women with a strong family history of breast cancer and BRCA1/2 mutation carriers, have several clinical options: risk-reduction surgery (bilateral mastectomy and bilateral oophorectomy), surveillance (mammography, clinical breast examination, and breast self-examination), and chemoprevention (tamoxifen). We review research in a number of areas central to our understanding of RRM, including recent data on 1) the effectiveness of RRM in reducing breast cancer risk, 2) the perception of RRM among women at increased risk and health-care providers, 3) the decision-making process for follow-up care of women at high risk, and 4) satisfaction and psychological status after surgery. We suggest areas of future research to better guide high-risk women and their health-care providers in the decision-making process.

Anticarcinogenic Agents↗
PubMed1993

Recurrent secretory carcinoma in residual mammary tissue after mastectomy.

A case of secretory carcinoma recurrent in residual breast parenchyma 8 years after modified radical mastectomy is described. The patient, 27 years old at the time of initial diagnosis, was disease free until two chest wall nodules appeared. The recurrent and primary carcinomas were identical and exhibited the mixed solid, papillary, and microacinar growth patterns characteristic of secretory carcinoma. Intraductal and invasive carcinoma involved fibrous tissue and mammary lobules remaining at the site of previous mastectomy. Immunohistochemical staining for alpha-lactalbumin was strongly positive; the carcinoma did not express estrogen or progesterone receptor proteins. Flow cytometric DNA analysis showed a diploid tumor with a synthetic phase of 10%. No further evidence of recurrent carcinoma developed during the ensuing 11 months of follow-up, without adjuvant chemotherapy or radiation. It is important to recognize the morphologic features of this unique form of invasive carcinoma because of its exceptionally good prognosis. Long-term follow-up is mandatory because of the potential for late locoregional recurrence, even after mastectomy.

Adult↗
PubMed1981

The curved lateral incision technique for subcutaneous mastectomy.

The inframammary incision often used for subcutaneous mastectomy provides somewhat limited exposure and often less than optimal aesthetic results, especially if the patient has ptosis preoperatively. This paper describes a technique for subcutaneous mastectomy that involves a straightforward marking system, provides excellent exposure, and produces satisfactory aesthetic results. This technique can be applied to most cases in which subcutaneous mastectomy is indicated.

Adult↗
PubMed1984

Subcutaneous mastectomy: an interim report on 1,244 patients.

Data are presented on 1,244 patients who had subcutaneous mastectomies during the past fourteen years with an average follow-up of seven years. Obscure lobular carcinoma in situ was found in 4.3% of patients and obscure ductal or intraductal carcinoma was found in 5.1%, for a total of 9.4%. Breast cancer developed in only 6 patients after subcutaneous mastectomy, an incidence of 0.5%, indicating that subcutaneous mastectomy is effective in preventing breast cancer. Where obscure breast cancer was found, the prevalent associated benign fibrocystic diseases were microcystic and macrocystic and lobular hyperplasia. Where obscure ductal or intraductal carcinoma was found, the prevalent associated benign diseases were microcysts, macrocysts, intraductal hyperplasia, and sclerosing adenosis.

Adult↗